Nalidixic acid
| |
| Nalidixic acid
| |
| Systematic (IUPAC) name | |
| 1-ethyl-7-methyl-4-oxo-[1,8]naphthyridine-3-carboxylic acid | |
| Identifiers | |
| CAS number | |
| ATC code | J01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C12H12N2O3 |
| Mol. mass | 232.235 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 90% |
| Metabolism | Partially Hepatic |
| Half life | 6-7 hours, significantly longer in renal impairment |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
B U.S. |
| Legal status | |
| Routes | Oral |
|
WikiDoc Resources for Nalidixic acid | |
|
Articles | |
|---|---|
|
Most recent articles on Nalidixic acid Most cited articles on Nalidixic acid | |
|
Media | |
|
Powerpoint slides on Nalidixic acid | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Nalidixic acid at Clinical Trials.gov Trial results on Nalidixic acid Clinical Trials on Nalidixic acid at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Nalidixic acid NICE Guidance on Nalidixic acid
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Nalidixic acid Discussion groups on Nalidixic acid Patient Handouts on Nalidixic acid Directions to Hospitals Treating Nalidixic acid Risk calculators and risk factors for Nalidixic acid
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Nalidixic acid | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Nalidixic acid is the basis for quinolone antibiotics.
Nalidixic acid is effective against both gram-positive and gram-negative bacteria. In lower concentrations, it acts bacteriostatically (that is, it inhibits growth and reproduction). In higher concentrations, it is bactericidal, meaning that it kills bacteria instead of merely inhibiting their growth.
It is especially used in treating urinary tract infections, caused for example by Escherichia coli, Proteus, Shigella, Enterobacter and Klebsiella.
External links
See also
Antibacterials for systemic use: topoisomerase inhibitors - quinolones (J01M) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Fluoroquinolones |
| ||||||||
| Other quinolones |
| ||||||||
| †Undergoing clinical trials. ‡ Withdrawn from market. § Veterinary use medications. | |||||||||
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
